We are live on
!
Find out more
PCM
Perkins Capital Management Portfolio holdings
AUM
$133M
1-Year Est. Return
127.86%
This Fund
S&P 500
This Quarter
Est. Return
+15.33%
1 Year Est. Return
+127.86%
3 Year Est. Return
+303.11%
5 Year Est. Return
+333.48%
10 Year Est. Return
–
AUM
$112M
AUM Growth
-$4.51M
(-3.9%)
Cap. Flow
-$14.3M
Cap. Flow
% of AUM
-12.78%
Top 10 Holdings %
Top 10 Hldgs %
35.03%
Holding
122
New
10
Increased
13
Reduced
73
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
QUMU
Qumu Corp.
QUMU
|
+$1.17M |
| 2 |
ASPU
ASPEN GROUP, INC.
ASPU
|
+$1.01M |
| 3 |
BIOL
Biolase, Inc.
BIOL
|
+$812K |
| 4 |
AKTS
Akoustis Technologies Inc
AKTS
|
+$759K |
| 5 |
FPAY
FlexShopper
FPAY
|
+$397K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTLP
Cantaloupe
CTLP
|
+$1.71M |
| 2 |
TEUM
Pareteum Corporation
TEUM
|
+$1.52M |
| 3 |
Apyx Medical
APYX
|
+$1.13M |
| 4 |
Natera
NTRA
|
+$995K |
| 5 |
Vericel Corp
VCEL
|
+$774K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 63.18% |
| 2 | Technology | 12.18% |
| 3 | Industrials | 6.62% |
| 4 | Communication Services | 6.04% |
| 5 | Consumer Staples | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Tactile Systems Technology
TCMD
$636M
| $1.44M | 1.29% |
21,350
-5,274
| -20% | -$292K |
|
27
BioLife Solutions
BLFS
$1.55B
| $1.32M | 1.18% |
81,550
-29,700
| -27% | -$483K |
|
28
AbbVie
ABBV
$455B
| $1.29M | 1.15% |
14,538
-2,450
| -14% | -$203K |
|
29
LifeVantage
LFVN
$79.4M
| $1.25M | 1.12% |
79,810
-358
| -0.4% | -$5.26K |
|
|
ASPU
30
DELISTED
ASPEN GROUP, INC.
ASPU
| $1.24M | 1.11% |
+155,300
| New | +$1.01M |
|
|
ATRS
31
DELISTED
Antares Pharma, Inc.
ATRS
| $1.21M | 1.08% |
256,833
-45,800
| -15% | -$187K |
|
|
IDXG
32
DELISTED
Interpace Biosciences, Inc. Common Stock
IDXG
| $1.15M | 1.03% |
229,589
-6,450
| -3% | -$41.7K |
|
|
QUMU
33
DELISTED
Qumu Corp.
QUMU
| $1.11M | 1% |
+427,000
| New | +$1.17M |
|
34
Bristol-Myers Squibb
BMY
$132B
| $1.1M | 0.99% |
17,175
-1,550
| -8% | -$88.8K |
|
|
BEAT
35
DELISTED
BioTelemetry, Inc.
BEAT
| $1.09M | 0.97% |
23,450
+8,450
| +56% | +$366K |
|
36
Merck
MRK
$321B
| $1.08M | 0.97% |
12,435
+131
| +1% | +$10.8K |
|
37
CVS Health
CVS
$134B
| $1.03M | 0.92% |
13,835
-1,415
| -9% | -$99.4K |
|
38
Aflac
AFL
$64.8B
| $1.02M | 0.91% |
19,250
-8,200
| -30% | -$435K |
|
39
Boston Scientific
BSX
$68.4B
| $1M | 0.9% |
22,183
-7,333
| -25% | -$307K |
|
40
Verizon
VZ
$193B
| $946K | 0.85% |
15,409
-1,925
| -11% | -$116K |
|
41
Castle Biosciences
CSTL
$813M
| $942K | 0.84% |
27,395
-525
| -2% | -$12.8K |
|
|
PFIE
42
DELISTED
Profire Energy, Inc
PFIE
| $891K | 0.8% |
614,800
+6,750
| +1% | +$11K |
|
43
Advanced Micro Devices
AMD
$791B
| $874K | 0.78% |
19,050
-800
| -4% | -$29.4K |
|
44
Ciena
CIEN
$52.7B
| $864K | 0.77% |
20,250
-4,000
| -16% | -$152K |
|
45
Sensus Healthcare
SRTS
$47.6M
| $840K | 0.75% |
237,186
-72,695
| -23% | -$329K |
|
|
AVGR
46
DELISTED
Avinger, Inc. Common Stock
AVGR
| $810K | 0.73% |
2,369
-280
| -11% | -$97.7K |
|
47
Microvision
MVIS
$85.7M
| $808K | 0.72% |
1,122,500
-4,000
| -0.4% | -$2.93K |
|
48
The Joint Corp
JYNT
$119M
| $802K | 0.72% |
49,710
-6,340
| -11% | -$115K |
|
49
Inuvo
INUV
$15.9M
| $792K | 0.71% |
267,943
-8,540
| -3% | -$24K |
|
|
CEMI
50
DELISTED
Chembio diagnostics, Inc.
CEMI
| $780K | 0.7% |
171,100
-22,200
| -11% | -$108K |
|
Similar funds
SVP
PWP
BF
SFG
HWMG
FTEA
WT
BAM
Perkins Capital Management's Q4 2019 Portfolio in Review
As of Q4 2019, Perkins Capital Management held 122 positions worth $112M, down 3.9% from $116M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Perkins Capital Management withdrew a net $14.3M in Q4 2019, closing 9 positions and reducing 73 holdings. Its most notable exit was Cantaloupe, an estimated $1.71M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, up from 62% a quarter earlier, followed by Technology and Industrials.
Against the trend, Perkins Capital Management opened a new position in Qumu Corp. worth $1.11M.
- Perkins Capital Management's largest Q4 2019 buy was Qumu Corp.: 427,000 shares worth $1.11M.
- Perkins Capital Management added most to Akoustis Technologies Inc in Q4 2019, an estimated $759K increase.
- Perkins Capital Management's biggest Q4 2019 reduction was Apyx Medical, cutting an estimated $1.13M.
- Perkins Capital Management fully exited Cantaloupe in Q4 2019, selling an estimated $1.71M.
- Perkins Capital Management's ten largest holdings make up 35% of its $112M portfolio in Q4 2019.
- Perkins Capital Management opened 10 new positions and closed 9 in Q4 2019.
- Perkins Capital Management's portfolio value fell 3.9% quarter-over-quarter to $112M.
Based on Perkins Capital Management's 13F filing for Q4 2019, filed 3 Feb 2020.